文献速递糖尿病

肾脏疾病:1型糖尿病被遗忘的遗产

Kidney Disease: The Forgotten Legacy of Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2025-01-01

综述指出1型糖尿病伴随肾功能进行性下降,现有标准治疗虽减少大量白蛋白尿型快速进展肾病并改善生存,但未减缓多数患者的肾功能下降。近十年出现GLP-1受体激动剂、醛固酮拮抗剂和SGLT2抑制剂等新肾保护策略,在2型糖尿病合并肾病患者中显示明确活性,但用于1型糖尿病前需在临床试验中验证疗效与安全性平衡。

要点

  • 1型糖尿病与肾功能进行性下降相关,现有治疗未减缓多数患者肾功能下降。
  • 需将早期肾脏保护置于与血糖控制同等重要的基础策略地位。
  • GLP-1受体激动剂、醛固酮拮抗剂和SGLT2抑制剂在2型糖尿病合并肾病中显示明确活性,用于1型糖尿病前需临床试验验证。

核心结论

  • 亟需为1型糖尿病建立将早期肾脏保护视为与血糖控制同等重要的不同基础策略。

研究设计与样本

  • 综述,考虑辅助治疗在1型糖尿病中改善肾脏结局的潜在作用。

主要发现

  • 当前标准治疗显著降低以大量白蛋白尿为特征的快速进展性肾病发病率并改善患者生存,但未减缓多数患者的肾功能下降。
  • 近十年出现的新肾保护策略包括胰高血糖素样肽1受体激动剂、醛固酮拮抗剂和钠-葡萄糖协同转运蛋白2抑制剂。
  • 每种疗法在2型糖尿病合并肾病患者中均显示明确活性,促使部分临床医生在1型糖尿病患者中超说明书使用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在将重要获益转化至1型糖尿病患者前,必须仔细考虑严重不良事件风险并在临床试验中验证疗效与安全性平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 1 diabetes is associated with a progressive decline in kidney function. With improved survival, more individuals with type 1 diabetes are reaching an age where irreversible loss of kidney function can impact health and clinical outcomes. Although current standard of care has markedly reduced the incidence of fast-progressing kidney disease characterized by heavy albuminuria, and improved patient survival, these same interventions have not slowed kidney decline in most patients. An urgent need remains to develop a different foundational approach to type 1 diabetes with early kidney protection considered as important as glucose control. Toward this goal, a number of new renoprotective strategies have emerged over the last decade, including glucagon-like peptide 1 receptor agonists, aldosterone antagonists, and sodium-glucose cotransporter 2 inhibitors. For each therapy unequivocal activity has been demonstrated in patients with type 2 diabetes and kidney disease, which has prompted some clinicians to use agents off-label in patients with type 1 diabetes, so pressing is their need. However, before such important benefits can be translated to patients with type 1 diabetes, the risk of serious adverse effects must be carefully considered and the balance of efficacy and safety verified in clinical trials. In this review we consider the potential role of adjunctive therapy in type 1 diabetes in improving kidney outcomes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Thomas MC, Zoungas S, Hanssen NMJ, et al. Kidney Disease: The Forgotten Legacy of Type 1 Diabetes. Diabetes Care. 2025. PMID: 40478448. doi:10.2337/dci25-0028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。